AUPH - צמיחת מכירות משנה לשנה (TTM) auriniapharma.com

Aurinia Pharmaceuticals (AUPH) employs an asset-light strategy by outsourcing the production of lupus nephritis drugs to Lonza plants, which makes the business dependent on logistics. The TTM revenue growth rate compared to last year, as provided by the GURU.Markets system, shows that the parameter value is 21.20. Stability is maintained through the distribution of approved drugs in the US, while high loyalty among patients with rare diagnoses ensures minimal customer churn.
פילוחי נתונים אנליטיים מרוכזים עבור Aurinia Pharma (AUPH)

The supply efficiency of drugs for the therapy of autoimmune pathologies and the high business margins of Aurinia Pharmaceuticals (AUPH) directly determine the dynamics of operating revenues. This metric measures the percentage change in revenue over a rolling year, allowing investors to assess sales scaling rates and the stability of the commercial cycle, which clearly reflects the YoY revenue growth trend for TTM.